Acyclovir treatment of varicella in otherwise healthy children1

https://doi.org/10.1016/S0022-3476(05)81618-XGet rights and content

Study objective: To determine whether acyclovir administered orally affects the duration and severity of varicella in otherwise normal children.

Design: Randomized, placebo-controlled, double-blind trial.

Setting: Patients' residence and university hospital clinic.

Patients: One hundred five children between 5 and 16 years of age with laboratory-confirmed varicella entered the study. Of the 102 who were included in the final analysis, 50 received acyclovir and 52 received placebo.

Interventions: Placebo or acyclovir was given orally four times daily, for 5 to 7 days. The acyclovir dose was adjusted as follows: 5 to 7 years of age, 20 mg/kg; 7 to 12 years, 15 mg/kg; and 12 to 16 years, 10 mg/kg.

Measurements and main results: Acyclovir recipients, compared with the placebo group, defervesced sooner (median, 1 day vs 2 days; p=0.001), experienced onset of cutaneous healing sooner, as reflected by a decrease in number of lesions (median, 3 days vs 2 days; p=0.002), and had fewer skin lesions (median, 500 vs 336; p=0.02). Acyclovir did not significantly change the rate of complications of varicella (10% in the acyclovir group vs 13.5% among placebo subjects). Adverse drug effects were not observed. Acyclovir recipients had lower geometric mean serum antibody titers to varicella-zoster virus than their placebo counterparts 4 weeks after the onset of illness, but antibody titers in both groups were similar 1 year later.

Conclusions: These results provide evidence that acyclovir is useful and well tolerated for treatment of varicella in otherwise healthy children.

References (14)

There are more references available in the full text version of this article.

Cited by (167)

  • Varicella and herpes zoster in children

    2020, Journal de Pediatrie et de Puericulture
  • Varicella Vaccines

    2017, Plotkin's Vaccines
  • Polish consensus guidelines on the use of acyclovir in the treatment and prevention of VZV and HSV infections

    2016, Journal of Infection and Chemotherapy
    Citation Excerpt :

    A double-blind study assessing the administration of acyclovir (80 mg/kg/day) for 5 days in 815 otherwise healthy children aged 2–12 years old, beginning within 24 h of the onset of a rash, showed a significant reduction in the number of lesions (by approx. 25%) and a one day reduction in the number of days with a fever. The treatment had no effect on the number of complications [1,2]. However, in adolescents and adults the treatment reduced the number of residual hypopigmented lesions on the skin [3].

  • Vaccination against varicella as post-exposure prophylaxis in adults: A quantitative assessment

    2015, Vaccine
    Citation Excerpt :

    Assuming this proportion was 9.16% as reported in Hanslik et al. [15], number of avoided cases and hospitalizations were more than two times higher: 29 cases and 0.5 hospitalizations avoided per 100,000 adults per year; (3) the efficacy of post-exposure vaccination may be as high as 100% if done early after exposure [12–14,19,27]. As we used 75% efficacy, up to 25% more cases could be avoided; (4) we considered that severity would be independent of the nature of exposure, although intensity of symptoms and number of lesions are higher in familial exposure cases [28–30]. If all severe cases arose from familial exposure, up to 67% hospitalizations could be avoided; (5) we limited assessment to directly avoided cases, and did not take into account cases avoided in pregnant women which may lead to severe sequelae in fetus.

  • Nosocomial Herpesvirus Infections

    2014, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases
  • Chickenpox and Herpes Zoster (Varicella-Zoster Virus)

    2014, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases
View all citing articles on Scopus
1

Supported by grants from the Burroughs Wellcome Company and the Minnesota Medical Foundation.

*

Now at Baylor College of Medicine, Houston, Texas.

View full text